{
  "citations" : [ {
    "@id" : "https://pharmgkb.org/literature/7283333",
    "@context" : "https://api.pharmgkb.org/jsonld/literature.jsonld",
    "id" : 7283333,
    "resourceId" : "21412232",
    "title" : "Pharmacogenetics: from bench to byte--an update of guidelines.",
    "_sameAs" : "https://www.ncbi.nlm.nih.gov/pubmed/21412232",
    "authors" : [ "Swen J J", "Nijenhuis M", "de Boer A", "Grandia L", "Maitland-van der Zee A H", "Mulder H", "Rongen G A P J M", "van Schaik R H N", "Schalekamp T", "Touw D J", "van der Weide J", "Wilffert B", "Deneer V H M", "Guchelaar H-J" ],
    "hasKeyword" : true,
    "journal" : "Clinical pharmacology and therapeutics",
    "meshDiseases" : [ ],
    "meshTerms" : [ "Animals", "Aryl Hydrocarbon Hydroxylases", "Cytochrome P-450 CYP2C9", "Drug Administration Schedule", "Drug-Related Side Effects and Adverse Reactions", "Humans", "Pharmaceutical Preparations", "Pharmacogenetics", "Practice Guidelines as Topic" ],
    "month" : 5,
    "nonHuman" : false,
    "objCls" : "Literature",
    "page" : "662-73",
    "pgkbPublication" : false,
    "pubDate" : "2011-05-01T00:00:00-07:00",
    "summary" : "Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPD), vitamin K epoxide reductase (VKORC1), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL).",
    "type" : "Article",
    "version" : 2,
    "volume" : "89",
    "xrefs" : [ {"@id":"https://pharmgkb.org/crossReference/pubMed/21412232","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":769250885,"resource":"PubMed","resourceId":"21412232","_url":"https://www.ncbi.nlm.nih.gov/pubmed/21412232"}, {"@id":"https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449247827,"resource":"DOI","resourceId":"10.1038/clpt.2011.34","_url":"http://dx.doi.org/10.1038%2Fclpt.2011.34"} ],
    "year" : 2011
  } ],
  "guideline" : {
    "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166104962",
    "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
    "objCls" : "Guideline Annotation",
    "id" : "PA166104962",
    "name" : "Annotation of DPWG Guideline for propafenone and CYP2D6",
    "cancerGenome" : false,
    "descriptiveVideoId" : "",
    "guidelineGenes" : [ ],
    "history" : [ {
      "id" : 1183704521,
      "date" : "2011-08-10T00:00:00-07:00",
      "type" : "Create",
      "version" : 0
    }, {
      "id" : 1450415030,
      "date" : "2019-05-23T14:33:30.713-07:00",
      "description" : "Annotation current with November 2018 DPWG Guideline release",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1450821027,
      "date" : "2019-10-07T18:21:56.510-07:00",
      "description" : "No changes based on August 2019 guideline",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1450956352,
      "date" : "2020-01-31T13:46:20.579-08:00",
      "description" : "Updated link to 2011 DPWG methods",
      "type" : "Update",
      "version" : 0
    } ],
    "literature" : [ {"@id":"https://pharmgkb.org/literature/7283333","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":7283333,"resourceId":"21412232","title":"Pharmacogenetics: from bench to byte--an update of guidelines.","_sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/21412232","objCls":"Literature","type":"Article","xrefs":[{"@id":"https://pharmgkb.org/crossReference/pubMed/21412232","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":769250885,"resource":"PubMed","resourceId":"21412232","_url":"https://www.ncbi.nlm.nih.gov/pubmed/21412232"},{"@id":"https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449247827,"resource":"DOI","resourceId":"10.1038/clpt.2011.34","_url":"http://dx.doi.org/10.1038%2Fclpt.2011.34"}]}, {"@id":"https://pharmgkb.org/literature/15103288","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15103288,"resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf","title":"Dutch Pharmacogenetics Working Group Guidelines August 2019","_sameAs":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf","objCls":"Literature","type":"Web Page","xrefs":[{"@id":"https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1450815695,"resource":"URL","resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf","_url":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"}]}, {"@id":"https://pharmgkb.org/literature/15102465","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15102465,"resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","title":"Dutch Pharmacogenetics Working Group Guidelines November 2018","_sameAs":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","objCls":"Literature","type":"Web Page","xrefs":[{"@id":"https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1450415575,"resource":"URL","resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","_url":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"}]} ],
    "recommendation" : true,
    "relatedAlleles" : [ ],
    "relatedChemicals" : [ {
      "@id" : "https://pharmgkb.org/chemical/PA451131",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA451131",
      "name" : "propafenone",
      "version" : 10
    } ],
    "relatedGenes" : [ {
      "@id" : "https://pharmgkb.org/gene/PA128",
      "@context" : "https://api.pharmgkb.org/jsonld/gene.jsonld",
      "objCls" : "Gene",
      "id" : "PA128",
      "symbol" : "CYP2D6",
      "name" : "cytochrome P450 family 2 subfamily D member 6",
      "version" : 7888
    } ],
    "source" : "Dutch Pharmacogenetics Working Group",
    "summaryMarkdown" : {
      "id" : 1447981932,
      "html" : "<p>Reduce the dose of propafenone by 70% for CYP2D6 poor metabolizers, and monitor pimozide plasma concentrations or use an alternative drug for CYP2D6 intermediate and ultrarapid metabolizers.</p>\n",
      "version" : 1
    },
    "summaryVideoId" : "",
    "terms" : [ ],
    "textMarkdown" : {
      "id" : 1447981931,
      "html" : "<h3 id=\"november-2018-update\">November 2018 Update</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for propafenone based on CYP2D6 genotype. They recommend monitoring plasma concentrations and performing an ECG or selecting an alternative antiarrhythmic drug for CYP2D6 ultrarapid metabolizers (UMs) and intermeidate metabolizers (IMs). They also recommend that patients who are CYP2D6 poor metabolizers (PMs) receive 30% of a standard dose of propafenone.</p>\n<p><em>Wording in table taken from the <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf\" target=\"_blank\">Dutch guidelines</a>.</em></p>\n<table class=\"table\">\n<thead>\n<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>\n</thead>\n<tbody>\n<tr><td>CYP2D6 UM</td><td>propafenone</td><td>Genetic variation decreases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This increases the risk of reduced or no efficacy</td><td>It is not possible to offer adequately substantiated recommendations for dose adjustment based on the literature.<br/>1. Either monitor plasma concentrations, perform an ECG and be alert to reduced efficacy of the therapy.<br/>2. Or choose an alternative. Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone.</td></tr>\n<tr><td>CYP2D6 IM</td><td>propafenone</td><td>Genetic variation increases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This may increase the risk of side effects.</td><td>It is not possible to offer adequately substantiated recommendations for dose adjustment based on the literature.<br/>1. Either guide the dose by therapeutic drug monitoring, perform an ECG and be alert to side effects<br/>2. Or choose an alternative. Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone.</td></tr>\n<tr><td>CYP2D6 PM</td><td>propafenone</td><td>Genetic variation increases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This increases the risk of side effects.</td><td>Reduce the dose to 30% of the standard dose, perform an ECG and monitor plasma concentrations.</td></tr>\n</tbody>\n</table>\n<p><a rel=\"noopener noreferrer\" href=\"https://www.g-standaard.nl/risicoanalyse/B0001596.PDF\" target=\"_blank\">Read for more information about this recommendation</a>, <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Read about gene information from DPWG</a></p>\n<h3 id=\"2011-guideline\">2011 Guideline</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for propafenone based on CYP2D6 genotype [Article:<a href=\"/pmid/21412232\">21412232</a>].  They suggest a reduced dose for poor metabolizers, and adjusting dose according to plasma concentrations or using an alternative drug for intermediate and ultrarapid metabolizers.</p>\n<table class=\"table\">\n<thead>\n<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>\n</thead>\n<tbody>\n<tr><td>PM (2 inactive alleles)</td><td>Reduce dose by 70%, record ECG, monitor plasma concentration</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10 <sup>9</sup>/l; leucopenia 2.0-3.0x10 <sup>9</sup>/l; thrombocytopenia 50-75x10 <sup>9</sup>/l</td></tr>\n<tr><td>IM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele)</td><td>Insufficient data to allow calculation of dose adjustment. Adjust dose in response to plasma concentration and record ECG or select alternative drug (e.g., sotalol, disopyramide, quinidine, amiodarone)</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms male, &lt;470 ms female); INR increase &lt; 4.5, Kinetic effect (S)</td></tr>\n<tr><td>UM (gene duplication in absence of inactive or decreased activity alleles)</td><td>Insufficient data to allow calculation of dose adjustment. Adjust dose in response to plasma concentration and record ECG or select alternative drug (e.g., sotalol, disopyramide, quinidine, amiodarone)</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (&gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR &gt; 6.0; neutropenia 0.5-1.0x10 <sup>9</sup>/l; leucopenia 1.0-2.0x10 <sup>9</sup>/l; thrombocytopenia 25-50x10 <sup>9</sup>/l; severe diarrhea</td></tr>\n</tbody>\n</table>\n<table class=\"table\">\n<thead>\n<tr><th>Allele Type</th><th>Alleles</th></tr>\n</thead>\n<tbody>\n<tr><td>active</td><td>*1, *2, *33, *35</td></tr>\n<tr><td>decreased activity</td><td>*9, *10, *17, *29, *36, *41</td></tr>\n<tr><td>inactive</td><td>*3-*8, *11-*16, *19-*21, *38, *40, *42</td></tr>\n</tbody>\n</table>\n<ul>\n<li>*See <a href=\"http://www.pharmgkb.org/page/dpwg\">Methods </a> or [Article:<a href=\"/pmid/18253145\">18253145</a>] for definition of &quot;good&quot; and &quot;moderate&quot; quality.</li>\n<li>S: statistically significant difference.</li>\n</ul>\n",
      "version" : 11
    },
    "userId" : "cfthorn",
    "version" : 21,
    "xrefs" : [ ]
  }
}